NCT05873205 2026-03-02
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
5 trialsNCT06648889 2026-01-15
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
Goethe University
Phase 2 Recruiting
NCT06517017 2025-11-28
UltraFrailMM
University of Utah
Phase 2 Recruiting
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT02999633 2022-03-21
ISLAY
Sanofi
Phase 2 Terminated